New Software, Catheter Enable Faster 3-D Mapping, Ablation
June 24, 2010 – The U.S. Food and Drug Administration (FDA) has cleared a new catheter and software for treating cardiac arrythmias. Biosense Webster Inc. announced yesterday that the FDA has cleared for marketing the CartoXPress Software Module and the Lasso NAV Circular Mapping Catheter for use with the Carto XP Mapping System.
The new software will allow electrophysiologists to visualize the Lasso Catheter and will be able to utilize the Fast Anatomical Mapping (FAM) feature that, up until now, was only available on Biosense Webster’s more recent Carto 3 Mapping and Ablation System. FAM rapidly and accurately creates high-resolution, CT-like maps, and also permits detailed visual enhancement of a specific area of interest within the heart.
All of the enhancements offered by the CartoXPress Software Module and the Lasso NAV Catheter have been developed to streamline and simplify workflow in the EP lab and enhance an electrophysiologist’s ability to diagnose and treat a wide array of simple and complex cardiac arrhythmias.
For more information: www.biosensewebster.com
More like this
- Biosense Webster Showcases Seamless Angiography, Carto3 Mapping Integration
- Biosense Webster Launches Carto 3 Multi-Electrode Mapping System
- Biosense Webster Forges Big-Name Alliances
- Biosense Webster Receives FDA Clearance for CARTO 3 EP Navigation System
- Biosense Webster Showcases New Navigational EP Mapping System at EUROPACE